GSK Reveals Recovery Strategy

BMI View: India's pharmaceutical market beguiles multinational pharmaceutical companies. Sales of medicines are booming and red tape will prevent systematic price cuts, which is a nascent trend in developing countries. A rapidly increasing prevalence of non-communicable diseases, such as hypertension, diabetes and cardiovascular conditions, also appeals to foreign firms and their product portfolios of medicines targeting chronic illnesses. However, India's intellectual property regime fails to acknowledge incremental innovation, discouraging many multinationals from launching products or making fixed capital investments.

To read the full article, please choose one of the following options: